Multiple Myeloma

Protocol #SponsorProtocol Title
NCT01734928

Celgene Corporation
CC-4047-MM-007
A Phase 3, Multi-Center, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

NCT02252172Janssen Research & Development, LLC
CR104762, 54767414MMY3008, 2014-002273-11
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma Who are Ineligible for High Dose Therapy
NCT02576977Merck Sharp & Dohme Corp.
3475-183, 2015-002509-13
A Phase III Study of Pomalidomide and Low Dose Dexamethasone with or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM). (KEYNOTE 183)

The treatment of Multiple Myeloma has rapidly evolved over the past decade with significant improvement in survival attributed to hematologic stem cell transplant and novel agents such as the proteasome inhibitor bortezomib (Velcade┬«) and the thalidomide derivative (‘imid’), lenalidomide (Revlimid┬«). NGOC is currently participating in trials of a second generation proteasome inhibitor (Ixazomib), a third generation ‘imid’ (pomolidomide), and a novel monoclonal antibody (daratumumab).